SUMMARY An attempt was made to see if it was possible to produce antimicrobial activity in colostrum after killed Escherichia coli 01l1 vaccine had been given orally to expectant mothers. The colostral samples were used in vitro for the inhibition test immediately after the start of lactation. The colostrum from 7 of the 47 vaccine-treated mothers inhibited the growth of E.coli 0111 compared with only one colostrum from 101 controls. No complication has occurred either in the vaccine-treated mothers or their suckling babies. The association between the presence of antimicrobial activity in the colostrum and the time of vaccine application was insignificant.
The protective role of breast milk against infections of newborn infants is well accepted.'-3 The mammary gland is a potent immunological organ and produces active macrophages, lymphocytes,2 4 and secretory immunoglobulin A (SIgA). This is resistant to acid degradation and to the action of proteolytic enzymes5 which make up almost half the protein content of the early colostrum.6 It is striking that human milk contains SIgA antibodies to many bacterial and viral antigens7; these antibodies are directed mainly against the mother's own gastrointestinal flora. It seems possible that lymphoid cells from the Peyer's patches, triggered antigenically, might home to mammary glands producing specific SIgA-antibodies.7-8 In this way the mother produces in her milk specific SIgA antibodies against the bacteria in her intestine8 and her breast-fed baby who may be exposed to these bacteria is protected against them. This phenomenon 'homing' is an important protection for suckling infants against both enteric and systemic infections, and it would seem desirable to Our study was undertaken in an attempt to produce a colostral antibacterial response after killed E. coli 0111 vaccine had been given orally to the expectant mother.
Materials and methods
The study was made between 1 January and 30 November 1978 and comprised 148 expectant mothers. 47 of them had been vaccinated, and 101 served as controls, the women being selected randomly. The expectant mothers were those admitted at term. Some of them were in labour and others were awaiting its onset. Thus some mothers received vaccine for only 1 day and others for up to 15 days before they started to lactate and to produce colostrum. In both vaccinated and control groups the stool samples for isolation of enteropathogenic E. coli were obtained immediately after admission to hospital. Stool-positive mothers were excluded 458 from the study. Women in the treated group were given E. coli 0111 vaccine 1 ml three times daily before meals by mouth from the time of their admission to the time that lactation began. After the start of lactation the colostrum was sampled by manual expression and taken immediately to the department of microbiology. Colostrum samples were similarly obtained from the untreated group. No mother from either group received any antibiotic or drug that was likely to have antimicrobial activity. Preparation of vaccine. Three different strains of E. coli 0111 were used: two had been isolated from hospital patients and one came from a microbiological collection of strains. After 24 hours of incubation the strains were washed off with saline and diluted after McFarland10 to give a suspension density of approximately 109 bacteria per ml. Inactivation was carried out in an Arnold apparatus at 1150C for 120 minutes. Tests of sterility and toxicity performed in vitro and on mice and guineapigs were negative. The safety of the vaccine was tested by volunteers from the paediatric staff, who developed no symptoms within 2 days of taking the vaccine.
The inhibitory activity of colostrum was investigated by an agar-diffusion test against homologous E. coli 0111 strains. Holes 6 mm in diameter in the agar plate were filled with 0 l ml colostrum, and the inhibition zone of bacterial growth was evaluated after 24 hours of incubation. Inhibition extending more than 6 mm (the diameter of hole) was accepted as being positive (Figure) .
Most of the vaccine-treated mothers tolerated the vaccine well. The only two exceptions vomited after ingestion and were excluded from the study. We tried to find out if the colostrum of treated mothers had more antimicrobial activity in vitro than that of the controls. We also tried to find out how long the vaccine should be given to obtain the best effect.
Results
The antimicrobial activity of colostrum after vaccination is shown in Table 1 . Colostrum was obtained from 47 vaccine-treated mothers, 7 of whom had antimicrobial activity in their colostrum. In the 101 controls only one sample was positive. The difference is highly significant (P<0 001).
In the group of treated mothers we attempted to relate the number of 'positive reacting' mothers to the time of vaccination before lactation. At first sight ( The results of the present study however, indicate that oral application of a heat-killed E. coli vaccine can also induce antibacterial activity in colostrum. Since we have not investigated the specificity of this activity we cannot rule out the possibility that it is mediated by one or more of the nonspecific antimicrobial components contained in mammary secretions. ' 
